NICE Publish Determination on Secukinumab (Cosentyx) for Psoriasis…
29th May 2015
New Biologic Treatment for Severe Psoriasis
The British London 10K Run - 2015…
27th May 2015
Places are still up for grabs!
Website Review – We’d Love Your Feedback…
20th May 2015
We're due to review our website and forum and we'd love your feedback.
Donate with confidence…
19th May 2015
The Psoriasis Association is a member of the Fundraising Standards Board, and as such you can give with confidence
Psoriasis Association Welcomes New Chair…
11th May 2015
Nick Evans was elected at the Annual General Meeting, 2015.
Our Achievements 2014 Published …
8th May 2015
2014 Annual Review available online now
NICE Publish Determination on Secukinumab (Cosentyx) for Psoriasis
On 29th May 2015, the National Institute for Health and Care Excellence (NICE) published their Final Appraisal Determination for Secukinumab for treating moderate to severe plaque psoriasis. The guidance is as follows:
Secukinumab is recommended, within its marketing authorisation, as an option for treating adults with plaque psoriasis only when:
• the disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10
• the disease has failed to respond to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them
This means that the criteria for treatment with secukinumab is severe psoriasis – the same as is currently in place for existing biologic treatment.
Commenting on today’s positive recommendation, Professor Chris Griffiths, Foundation Professor of Dermatology University of Manchester said, “Psoriasis is a common, life-long debilitating condition which has a significant impact on every aspect of the lives of those afflicted with it. Our participation in the secukinumab clinical trial programme has shown us first-hand its impact on patients by delivering high levels of skin clearance. As NICE has recognised in its Final Appraisal Determination, secukinumab is an innovative medicine and represents a step change in the management of psoriasis. I am delighted that NICE has moved quickly to make secukinumab available within the NHS and that people with psoriasis will now have a real opportunity to achieve clear skin.”
Helen McAteer, Chief Executive of the Psoriasis Association said, “Psoriasis is so much more than just a skin condition; it can be life consuming, affecting psychological wellbeing as well as physical health. Today’s news offers promise for many people with psoriasis who are striving for clear skin. I hope that this guidance will be implemented swiftly in order that patients can appropriately access this new treatment as soon as possible.”
A Final Appraisal Determination, which has been published for secukinumab, is the last step in the review process, and is used as a basis for NICE’s final guidance to the NHS, providing no appeals are made by those who consulted during the process. The final guidance for secukinumab in psoriasis is expected to be published in July 2015.
For more information on secukinumab (Cosentyx), visit our Biologic Treatments for Psoriasis section.